Travere Therapeutics, Inc.

Historical 13F Holders

Symbol
TVTX
CUSIP
89422G107
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 89422G107 since 12/18/2024, largest first.

Filer % of Class Filed
Janus Henderson Group PLC 13G/A 11.9% 11/14/2025
Event 9/30/2025
FMR LLC 13G/A
7.7% 8/6/2026
Event 6/30/2026
BlackRock, Inc. 13G/A 7.5% 4/17/2025
Event 3/31/2025
Bank of America Corp /DE/ 13G 5.8% 8/12/2026
Event 6/30/2026
Vanguard Capital Management LLC 13G 5.1% 4/30/2026
Event 3/31/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (7)
Perceptive Advisors LLC 13G/A
4.8% 2/17/2026
Event 12/31/2025
State Street Corp 13G 4.6% 8/7/2026
Event 6/30/2026
Rock Springs Capital Management LP 13G/A
3.3% 5/15/2025
Event 3/31/2025
Woodline Partners LP 13G/A 2.4% 2/14/2025
Event 12/31/2024
Armistice Capital, LLC 13G/A
1.7% 8/14/2026
Event 6/30/2026
Macquarie Group Ltd 13G/A
0% 2/13/2026
Event 12/31/2025
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 8 103 k $6.08 M
2026 Q2 336 111 M $6.10 B
2026 Q1 283 101 M $3.01 B
2025 Q4 304 102 M $3.91 B
2025 Q3 268 101 M $2.42 B
2025 Q2 230 102 M $1.51 B
2025 Q1 237 98.2 M $1.78 B
2024 Q4 214 95.2 M $1.66 B
2024 Q3 193 83.7 M $1.17 B
2024 Q2 185 92.5 M $772 M
2024 Q1 190 95.3 M $735 M
2023 Q4 183 91.7 M $825 M
2023 Q3 196 82.5 M $738 M
2023 Q2 181 82.8 M $1.27 B
2023 Q1 183 84.3 M $1.90 B
2022 Q4 166 77.2 M $1.62 B
2022 Q3 183 74.0 M $1.82 B
2022 Q2 181 69.7 M $1.69 B
2022 Q1 181 70.6 M $1.81 B
2021 Q4 191 67.8 M $2.10 B
2021 Q3 161 60.9 M $1.48 B
2021 Q2 148 63.3 M $930 M
2021 Q1 160 65.9 M $1.65 B
2020 Q4 152 53.5 M $1.46 B